Total Payments
$223,158
2024 Payments
$3,275
Companies
46
Transactions
981
Medicare Patients
5,504
Medicare Billing
$503,364
Payment Breakdown by Category
Other$157,586 (70.6%)
Consulting$22,018 (9.9%)
Travel$21,111 (9.5%)
Food & Beverage$17,788 (8.0%)
Research$4,574 (2.0%)
Education$82.19 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $157,586 | 107 | 70.6% |
| Consulting Fee | $22,018 | 13 | 9.9% |
| Travel and Lodging | $21,111 | 105 | 9.5% |
| Food and Beverage | $17,788 | 712 | 8.0% |
| Unspecified | $4,574 | 40 | 2.0% |
| Education | $82.19 | 4 | 0.0% |
Payments by Type
General
$218,584
941 transactions
Research
$4,574
40 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $62,942 | 268 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $56,189 | 110 | $0 (2019) |
| Mylan Specialty L.P. | $54,915 | 113 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $33,652 | 136 | $0 (2024) |
| Vapotherm Inc | $3,451 | 4 | $0 (2019) |
| Chiesi USA, Inc. | $2,159 | 4 | $0 (2024) |
| SANOFI US SERVICES INC. | $1,488 | 15 | $0 (2022) |
| Genentech USA, Inc. | $1,183 | 48 | $0 (2023) |
| Theravance Biopharma Inc. | $895.77 | 5 | $0 (2017) |
| JAZZ PHARMACEUTICALS INC. | $811.77 | 42 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,275 | 74 | GlaxoSmithKline, LLC. ($1,231) |
| 2023 | $17,397 | 70 | GlaxoSmithKline, LLC. ($14,630) |
| 2022 | $5,676 | 63 | GlaxoSmithKline, LLC. ($3,857) |
| 2021 | $13,871 | 74 | GlaxoSmithKline, LLC. ($8,620) |
| 2020 | $22,999 | 114 | Mylan Specialty L.P. ($15,592) |
| 2019 | $82,254 | 236 | Mylan Specialty L.P. ($39,241) |
| 2018 | $26,618 | 149 | Sunovion Pharmaceuticals Inc. ($19,349) |
| 2017 | $51,068 | 201 | Sunovion Pharmaceuticals Inc. ($27,807) |
All Payment Transactions
981 individual payment records from CMS Open Payments — Page 1 of 40
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $13.75 | General |
| Category: RESPIRATORY | ||||||
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $35.02 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/11/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $25.71 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $29.61 | General |
| Category: NEUROLOGY | ||||||
| 12/10/2024 | Avadel CNS Pharmaceuticals, LLC | LUMRYZ (Drug) | Food and Beverage | In-kind items and services | $15.44 | General |
| Category: CENTRAL NERVOUS SYSTEM CNS NEUROLOGY | ||||||
| 12/06/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $85.83 | General |
| Category: NEUROLOGY | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $19.61 | General |
| Category: Respiratory | ||||||
| 11/20/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $150.00 | General |
| 11/20/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $22.63 | General |
| Category: Pulmonology | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $20.95 | General |
| Category: Respiratory | ||||||
| 11/19/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $12.48 | General |
| Category: RESPIRATORY | ||||||
| 11/15/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $37.62 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/26/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $8.83 | General |
| Category: RESPIRATORY | ||||||
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $16.76 | General |
| Category: Respiratory | ||||||
| 10/16/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $28.85 | General |
| Category: Immunology | ||||||
| 10/15/2024 | Avadel CNS Pharmaceuticals, LLC | LUMRYZ (Drug) | Food and Beverage | In-kind items and services | $15.64 | General |
| Category: CENTRAL NERVOUS SYSTEM CNS NEUROLOGY | ||||||
| 10/11/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $26.52 | General |
| Category: NEUROLOGY | ||||||
| 10/06/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $98.81 | General |
| Category: Immunology | ||||||
| 10/04/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $17.84 | General |
| Category: IMMUNOLOGY | ||||||
| 10/02/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: Inflammation | ||||||
| 10/01/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $20.67 | General |
| Category: Respiratory | ||||||
| 09/25/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $19.57 | General |
| Category: Respiratory | ||||||
| 09/24/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $17.41 | General |
| Category: Respiratory | ||||||
| 09/18/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $37.62 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi | SANOFI US SERVICES INC. | $1,433 | 14 |
| A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | GlaxoSmithKline, LLC. | $1,413 | 7 |
| A Phase IIb, Randomized Stratified , Double Blind Sponsor Open , Parallel Group, Placebo Controlled, Dose Finding Study of Nemiralisib GSK2269557 Added to Standard of Care SoC Versus SoC Alone in Participants Diagnosed with an Acute Moderate or Seve | GlaxoSmithKline, LLC. | $651.95 | 5 |
| A PHASE III, 52 WEEK, RANDOMIZED, DOUBLE BLIND, 3-ARM PARALLEL GROUP S | GlaxoSmithKline, LLC. | $594.28 | 10 |
| A PHASE IIB, RANDOMIZED (STRATIFIED), DOUBLE-BLIND (SPONSOR OPEN), PAR | GlaxoSmithKline, LLC. | $97.05 | 2 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation | SANOFI US SERVICES INC. | $55.16 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 1,206 | 2,104 | $246,151 | $122,669 |
| 2022 | 17 | 1,281 | 2,065 | $253,837 | $123,881 |
| 2021 | 16 | 1,416 | 2,262 | $272,509 | $139,551 |
| 2020 | 18 | 1,601 | 2,196 | $242,906 | $117,263 |
Total Patients
5,504
Total Services
8,627
Medicare Billing
$503,364
Procedure Codes
76
All Medicare Procedures & Services
76 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 434 | 863 | $135,491 | $74,244 | 54.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 56 | 116 | $24,476 | $15,077 | 61.6% |
| 94375 | Test to measure rate of airflow | Office | 2023 | 194 | 494 | $37,050 | $13,557 | 36.6% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 79 | 79 | $7,505 | $5,682 | 75.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 33 | 33 | $7,722 | $3,607 | 46.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 80 | 80 | $2,400 | $2,352 | 98.0% |
| 95012 | Test to measure the level of nitric oxide gas | Office | 2023 | 60 | 154 | $4,620 | $2,065 | 44.7% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 41 | 41 | $6,150 | $1,729 | 28.1% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 38 | 38 | $5,700 | $1,556 | 27.3% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 41 | 41 | $6,642 | $1,139 | 17.1% |
| 94664 | Evaluation of use of breathing device | Office | 2023 | 50 | 55 | $2,915 | $717.75 | 24.6% |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | Office | 2023 | 41 | 51 | $2,040 | $493.42 | 24.2% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2023 | 20 | 20 | $1,100 | $169.99 | 15.5% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 19 | 19 | $1,140 | $149.91 | 13.2% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 20 | 20 | $1,200 | $129.96 | 10.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 443 | 823 | $129,211 | $71,721 | 55.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 65 | 118 | $24,898 | $15,996 | 64.2% |
| 94375 | Test to measure rate of airflow | Office | 2022 | 200 | 470 | $35,250 | $13,205 | 37.5% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 82 | 82 | $7,790 | $5,607 | 72.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 39 | 39 | $9,201 | $3,858 | 41.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 87 | 87 | $2,610 | $2,524 | 96.7% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Facility | 2022 | 18 | 20 | $8,956 | $1,714 | 19.1% |
| 95012 | Test to measure the level of nitric oxide gas | Office | 2022 | 55 | 119 | $3,570 | $1,681 | 47.1% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 30 | 30 | $4,500 | $1,346 | 29.9% |
| 94726 | Test to determine lung volumes using sensors | Office | 2022 | 29 | 29 | $4,350 | $1,210 | 27.8% |
About Dr. Thomas Siler, MD
Dr. Thomas Siler, MD is a Pulmonary Disease healthcare provider based in Saint Charles, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1881633931.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Siler, MD has received a total of $223,158 in payments from pharmaceutical and medical device companies, with $3,275 received in 2024. These payments were reported across 981 transactions from 46 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($157,586).
As a Medicare-enrolled provider, Siler has provided services to 5,504 Medicare beneficiaries, totaling 8,627 services with total Medicare billing of $503,364. Data is available for 4 years (2020–2023), covering 76 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Sleep Medicine, Critical Care Medicine
- Location Saint Charles, MO
- Active Since 06/05/2006
- Last Updated 05/18/2011
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1881633931
Products in Payments
- Yupelri (Drug) $54,833
- LONHALA MAGNAIR (Drug) $28,250
- UTIBRON (Drug) $25,781
- TRELEGY ELLIPTA (Drug) $25,428
- BEVESPI AEROSPHERE (Drug) $21,292
- ANORO (Drug) $10,892
- NUCALA (Biological) $7,833
- Precision Flow (Device) $3,451
- BREZTRI (Drug) $2,978
- BREZTRI AEROSPHERE (Drug) $2,928
- SEEBRI (Drug) $1,849
- DUPIXENT (Drug) $1,534
- DUPIXENT (Biological) $1,174
- SYMBICORT (Drug) $959.77
- Xolair (Biological) $847.88
- ANORO ELLIPTA (Drug) $459.04
- TEZSPIRE (Biological) $381.23
- Prolastin-C Liquid (Biological) $354.30
- STIOLTO RESPIMAT (Drug) $347.48
- XYWAV (Drug) $346.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.